Tarsus Pharmaceuticals, Inc. ( (TARS) ) has released its Q3 earnings. Here is a breakdown of the information Tarsus Pharmaceuticals, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tarsus Pharmaceuticals, Inc. is a company that leverages scientific advancements and technology to innovate treatments primarily in the eye care sector, with a focus on addressing unmet medical needs. The company is known for its FDA-approved product, XDEMVY, which treats Demodex blepharitis, and is actively developing treatments for ocular rosacea and Lyme disease prevention.
In its third quarter of 2025, Tarsus Pharmaceuticals reported significant growth in net sales, reaching approximately $119 million, marking a 147% increase year-over-year. The company highlighted the strong commercial momentum of its product XDEMVY, with a notable rise in multi-patient prescribers, reflecting increased market penetration and acceptance among eye care professionals.
Key financial metrics for the quarter included net product sales of $118.7 million, a substantial increase from the previous year. The company delivered over 103,000 bottles of XDEMVY to patients, and achieved broad coverage across commercial, Medicare, and Medicaid plans. Despite increased costs in sales and R&D, Tarsus reduced its net loss to $12.6 million from $23.4 million in the same period last year.
Looking ahead, Tarsus is poised for continued growth with plans to initiate Phase 2 studies for new treatments targeting ocular rosacea and Lyme disease prevention. The company’s management remains optimistic about sustaining long-term growth through its strategic pipeline expansion and continued market education efforts.